Artificial Intelligence Has High Performance for Detecting PCOS
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 22, 2023 -- Artificial intelligence (AI) and machine learning (ML) have high diagnostic and classification performance for detection of polycystic ovarian syndrome (PCOS), according to a review published online Sept. 18 in Frontiers in Endocrinology.
Francisco J. Barrera, M.D., from the Harvard T. H. Chan School of Public Health in Boston, and colleagues conducted a systematic review of the literature to examine the utility of AI/ML in the diagnosis or classification of PCOS. Data from 31 studies were included in the review.
Ten studies employed standardized criteria, while 17 used clinical information with/without imaging. Support vector machine, K-nearest neighbor, and regression models were the most commonly used AI/ML techniques (42, 26, and 23 percent of studies, respectively). The researchers found that the areas under the receiver operating characteristic curve, which were employed to compare AI/ML to clinical diagnosis, varied from 73 to 100 percent; diagnostic accuracy varied from 89 to 100 percent; and sensitivity and specificity varied from 41 to 100 and from 75 to 100 percent, respectively. Positive predictive value ranged from 68 to 95 percent and negative predictive value ranged from 94 to 99 percent.
"Our findings suggest that there is a high potential of AI/ML based programs in the diagnosis and care of PCOS, but that future studies should focus on enhancing methodological robustness and incorporating variables and outcomes of clinical importance," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.